FDA Approves Qsymia for Long-Term Weight Loss in the US

The US Food and Drug Administration (FDA) has approved Qsymia, a weight-loss drug combining phentermine and topiramate. This medication is designed for long-term weight management in adults. However, it remains unavailable in Germany, where no prescriptions or official guidelines for its use exist.

Phentermine is an appetite suppressant often prescribed for short-term weight control. Topiramate, originally approved for epilepsy and migraines, is sometimes used off-label for weight loss. When taken together, studies suggest they may be more effective than when used separately.

A 2013 trial showed that patients taking 15 mg of phentermine with 92 mg of topiramate daily lost an average of 20 pounds over 28 weeks. This combination outperformed results from either drug alone. However, side effects can occur, including tingling, dizziness, fatigue, and dry mouth. In some cases, users have reported depression, fever, or flu-like symptoms, particularly in children. Doctors typically recommend phentermine once daily, usually in the morning, while topiramate is taken once or twice a day. Patients who do not see weight loss results are advised to consult their doctor for dose adjustments or alternative treatments.

Qsymia offers a new option for weight management in the US, backed by clinical evidence of its effectiveness. The drug's absence in Germany means no local prescriptions or medical recommendations are available. Patients considering this treatment should discuss potential benefits and side effects with their healthcare provider.